This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering



ANeuroTech is committed to bring an effective treatment for people that continue to suffer from depression with associated subjective cognitive problems and to the creation of substantial value for investors. We have comprehensive experience in the science and business of CNS drug discovery and development up till Market Authorization. The inception of ANeuroTech is the result of +3 decades of experience in the clinical development of neuroscience blockbusters in collaboration with established pharma companies. Our Founding CEO, Dr Erik Buntinx, MD, is a qualified Psychiatrist and Psychopharmacologist. Dr Erik Buntinx has been a Principal Investigator for various clinical trials as part of which he has observed several thousand patients. He has been involved in numerous programs on CNS blockbusters. Within his clinical research activities, Dr. Erik Buntinx discovered the unique clinical pharmacological properties of ANT01 based on which the ANeuroTech patents were filed. After the go-ahead from the FDA, achieved in 2Q 2023, ANeuroTech’s lead compound ANT01 is scheduled to start its Phase IIIB program for Adjunctive Treatment in Major Depression in 1Q 2024. Start-up preparations are ongoing in partnership with IQVIA Biotech. Based on our in-depth knowledge on involved brain mechanisms in depression, we believe that in contrast to the mechanism of action of current first line antidepressants such as the SSRIs/SNRIs, a highly selective 5-HT2A/D4 antagonist such as ANT01, is able to improve the innate emotional and cognitive brain function. We believe that key symptoms such as emotional blunting and cognitive impairment which are present as part of the pathophysiology of the target patients i.e., patients suffering from MDD, and which typically are not well responding to SSRIs/SNRIs, might be improved by ANT01. In addition, based on ANeuroTech’ Technology Platform, discovery of potential treatment paradigm shifting compound(s) has started in 3Q 2023.